Docetaxel-Induced Fatal Interstitial Pneumonitis in a Patient with Castration-Resistant Prostate Cancer

A 69-year-old man with castration-resistant prostate cancer (CRPC) received docetaxel and a corticosteroid. After the third cycle of docetaxel administration, he presented with dyspnea, cough, sputum, and fever of 39.2℃. The chest X-ray and chest computed tomography (CT) revealed a diffuse reticulonodular shadow in both lungs, which suggested interstitial pneumonitis. Initially, we used empiric broad-spectrum antibiotics and high-dose corticosteroids. However, his condition progressively became worse and he was transferred to the intensive care unit, intubated, and placed on mechanical ventilation. He died 4 days after hospital admission. Here we report this case of fatal interstitial pneumonitis after treatment with docetaxel for CRPC. We briefly consider docetaxel-induced pneumonitis to make physicians aware of the possibility of pulmonary toxicity so that appropriate treatment can be begun as soon as possible.

[1]  Y. Maehara,et al.  Severe interstitial pneumonitis associated with the administration of taxanes , 2010, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[2]  C. Grande,et al.  Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment , 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[3]  C. Wiedermann,et al.  Fatal Interstitial Pneumonitis Associated with Docetaxel Administration in a Patient with Hormone-Refractory Prostate Cancer , 2006, Tumori.

[4]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[5]  W. Read,et al.  Severe interstitial pneumonitis associated with docetaxel administration , 2002, Cancer.

[6]  R. Perng,et al.  Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere) , 2001, British Journal of Cancer.

[7]  F. Fossella Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials. , 1999, Seminars in oncology.

[8]  H. Choy,et al.  Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  C. Croce,et al.  Bcl2 is the guardian of microtubule integrity. , 1997, Cancer research.

[10]  T. Taguchi,et al.  Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.